- Home
- MITQ vs PPBT Comparison
MITQ vs PPBT Comparison
Compare MITQ & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MITQ | PPBT |
|---|---|---|
| Founded | N/A | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0M | 2.4M |
| IPO Year | 2019 | 2014 |
Fundamental Metrics
Financial Performance| Metric | MITQ | PPBT |
|---|---|---|
| Price | $0.61 | $1.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $30.00 |
| AVG Volume (30 Days) | 66.8K | ★ 2.0M |
| Earning Date | 05-15-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $20,139,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $58.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.42 | $0.41 |
| 52 Week High | $1.66 | $5.18 |
Technical Indicators
Market Signals| Indicator | MITQ | PPBT |
|---|---|---|
| Relative Strength Index (RSI) | 68.46 | 51.56 |
| Support Level | $0.60 | $1.35 |
| Resistance Level | $0.66 | $1.85 |
| Average True Range (ATR) | 0.05 | 0.22 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 61.24 | 22.32 |
Price Performance
Historical ComparisonAbout MITQ Moving iMage Technologies Inc.
Moving iMage Technologies Inc is engaged in providing designed equipment as well as other off the shelf cinema products needed for contemporary cinema requirements. It offers technical, design and consulting services such as custom engineering, systems design, integration and installation and digital technology, as well as software solutions for operations enhancement and theatre management.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.